1. Pathway of LCK Tyrosine Kinase and mTOR Signaling in Children with T-Cell Acute Lymphoblastic Leukemia
- Author
-
Rocka A, Suchcicka M, Jankowska AM, Woźniak MM, and Lejman M
- Subjects
t-all ,pediatric ,signaling pathways ,targeted therapy ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Agata Rocka,1 Maria Suchcicka,2 Aleksandra M Jankowska,2 Magdalena M Woźniak,1 Monika Lejman3 1Pediatric Radiology, Medical University of Lublin, Medical University of Lublin, Prof. Antoni Gębali 6, Lublin, 20-093, Poland; 2Student Scientific Society of Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Prof. Antoni Gębali 6, Lublin, 20-093, Poland; 3Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Prof. Antoni Gębali 6, Lublin, 20-093, PolandCorrespondence: Agata Rocka, Pediatric Radiology, Medical University of Lublin, Medical University of Lublin, Prof. Antoni Gębali 6, Lublin, 20-093, Poland, Email agatarocka2@gmail.comAbstract: The aim of this study is to analyze available research on targeting signaling pathways for the development of new drugs in patients with T-cell acute lymphoblastic leukemia (T-ALL). This analysis focuses specifically on the role of LCK tyrosine kinase and mTOR signaling pathways in pediatric patients. Outcome: Current literature suggests that these pathways play a significant role in the regulation of T-cell cycles, making them potential therapeutic targets. However, despite promising findings, there remains a need for further research, particularly in pediatric populations, to fully understand the therapeutic implications and to optimize drug development. The conclusion drawn from this analysis highlights the significant influence of LCK and mTOR on T-cell cycle regulation, underscoring the importance of continued investigation in this area.Keywords: T-ALL, pediatric, signaling pathways, targeted therapy
- Published
- 2024